MSD Enters into a Clinical Collaboration with IO to Evaluate IO102-IO103 + Keytruda as 1L Treatment of Metastatic Melanoma

 MSD Enters into a Clinical Collaboration with IO to Evaluate IO102-IO103 + Keytruda as 1L Treatment of Metastatic Melanoma

MSD Enters into a Clinical Collaboration with IO to Evaluate IO102-IO103 + Keytruda as 1L Treatment of Metastatic Melanoma

Shots:

  • The companies collaborated to evaluate IO’s IO102-IO103 + MSD’s Keytruda vs Keytruda alone in the P-III trial for patients with previously untreated unresectable or MM. Biomarker studies will also be conducted while IO will sponsor the trial & MSD will provide Keytruda
  • The P-I/II trial of combination therapy in 30 patients with the same indication demonstrated ORR (73%) & CR rate (47%). The therapy can induce tumor regression & establish durable antitumor response while achieving a manageable tolerability profile
  • IO102 & IO103 are the immune-modulatory vaccines targeting IDO & PD-L1. The therapy has received BTD from FDA for MM based on the P-I/II trial

Click here to­ read full press release/ article | Ref: PR Newswire | Image: IO Biotech

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post